<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of hypertension in patients with heart failure</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of hypertension in patients with heart failure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of hypertension in patients with heart failure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John D Bisognano, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen S Gottlieb, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William B White, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypertension is the most prevalent modifiable risk factor for the development of heart failure (HF) [<a href="#rid1">1</a>], both because hypertension increases cardiac work, which leads to the development of left ventricular hypertrophy (LVH), and because hypertension is a risk factor for the development of coronary heart disease. (See  <a class="medical medical_review" href="/d/html/3479.html" rel="external">"Epidemiology of heart failure"</a>.)</p><p>The incidence of HF in hypertensive patients varies according to the population and duration of follow-up. As an example, approximately 2 percent of high-risk hypertensive patients in the Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial developed HF at three years [<a href="#rid2">2</a>]. Among the high-risk hypertensive population enrolled into the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 1716 out of 32,804 participants developed HF during an average follow-up of nine years (5.4 percent) [<a href="#rid3">3</a>].</p><p>In contrast to the pattern seen in the general population, in which prognosis is poorer for hypertensive compared with normotensive individuals, a higher blood pressure prior to treatment is a predictor of better survival in patients with HF [<a href="#rid4">4</a>]. It is likely that this correlation is a consequence of the fact that more severe cardiac dysfunction causes a decline in systemic blood pressure, making low blood pressure a marker for more advanced HF [<a href="#rid4">4</a>]. This observation makes it difficult to study the benefits of antihypertensive therapy in this population. Goal blood pressure in patients with HF is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with heart failure'</a>.)</p><p>Treatment of hypertension in patients with HF must take into account the type of HF that is present: systolic dysfunction, in which impaired cardiac contractility is the primary abnormality; or diastolic dysfunction, in which there is a limitation to diastolic filling and therefore in forward output due to increased ventricular stiffness [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a>.)</p><p>The distinction between these two, not mutually exclusive types of HF can be made by assessment of left ventricular ejection fraction using echocardiography. (See  <a class="medical medical_review" href="/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a>.)</p><p>Establishing the type of HF that is present is important because it determines which antihypertensive agents should be used [<a href="#rid5">5</a>]. (See <a class="local">'Treatment of hypertension in patients with heart failure with reduced ejection fraction (HFrEF)'</a> below and <a class="local">'Treatment of hypertension in patients with heart failure with preserved ejection fraction (HFpEF)'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">TREATMENT OF HYPERTENSION IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFrEF)</span><span class="headingEndMark"> — </span>The goals of antihypertensive therapy in the setting of reduced ejection fraction are to reduce both preload (to diminish congestive symptoms) using diuretics and afterload (to improve cardiac output) using vasodilators (in particular, antagonists of the renin-angiotensin system). Neurohormonal blockade, such as with beta blockers or antagonists of the renin-angiotensin-aldosterone system, also improves cardiac contractility and may lower blood pressure. (See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p>Goal blood pressure in patients with heart failure (HF) with reduced ejection fraction (HFrEF) is discussed separately. (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with heart failure'</a>.)</p><p class="headingAnchor" id="H73782418"><span class="h2">Antihypertensive regimen in HFrEF</span><span class="headingEndMark"> — </span>In general, patients with hypertension and HF with reduced ejection fraction (HFrEF) should be treated, if possible, with a renin angiotensin system (RAS) inhibitor (ie, an angiotensin receptor-neprilysin inhibitor, angiotensin converting enzyme [ACE] inhibitor, or an angiotensin receptor blocker [ARB]), a beta blocker, and a mineralocorticoid receptor antagonist. In addition to the mortality benefit associated with this regimen in patients with HFrEF, many patients will experience a minor to moderate improvement in their ejection fraction, with occasional patients experiencing substantial improvement. Each of these medications has an incremental benefit when added to the others. </p><p>To maximize clinical improvement, it is important, whenever possible, to try to attain the target doses of these medications that were used in the clinical trials. The use of these medications in patients with HFrEF is presented in detail in other topics. (See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a>.)</p><p>Diuretics are used to treat symptomatic hypervolemia (pulmonary and/or peripheral edema) or to further reduce blood pressure, if needed, in hypervolemic patients. (See  <a class="medical medical_review" href="/d/html/3512.html" rel="external">"Use of diuretics in patients with heart failure"</a>.)</p><p>Therapy with nondihydropyridine calcium blockers is not recommended because of their lack of benefit in this population [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H3"><span class="h3">Renin-angiotensin antagonists</span><span class="headingEndMark"> — </span>RAS inhibitors, given to patients with mild to advanced HF (many of whom are not hypertensive), increase cardiac output, diminish congestive symptoms, reduce the rate of progressive cardiac dysfunction, and decrease cardiovascular mortality at one to four years (<a class="graphic graphic_figure graphicRef70015" href="/d/graphic/70015.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>]. The drugs also benefit patients with asymptomatic left ventricular dysfunction (<a class="graphic graphic_figure graphicRef75136" href="/d/graphic/75136.html" rel="external">figure 2</a>) [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/3509.html" rel="external">"Management and prognosis of asymptomatic left ventricular systolic dysfunction"</a> and  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults", section on 'Pharmacologic therapy'</a>.)</p><p>Despite these beneficial cardiovascular effects, RAS inhibitors generally do not improve kidney function in patients with HF. To the contrary, there is a rise (usually modest) in the plasma creatinine concentration in approximately 30 percent of cases [<a href="#rid9">9</a>]. This complication is most likely to occur in patients in whom maintenance of the glomerular filtration rate is dependent upon angiotensin II, such as those on high-dose diuretic therapy. These patients are also at greater risk of first-dose hypotension. The RAS inhibitor does not generally need to be discontinued unless there is an increase in plasma creatinine that exceeds 30 to 35 percent from baseline or the plasma creatinine continues to rise and does not stabilize. Care must be taken not to attribute laboratory abnormalities that may be due to excessive diuresis to the effect of the RAS inhibitor. (See  <a class="medical medical_review" href="/d/html/2365.html" rel="external">"Renal effects of ACE inhibitors in heart failure"</a>.)</p><p>Simultaneous treatment with two RAS inhibitors (eg, combination therapy with an ACE inhibitor and ARB) should be avoided [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Combination of ACE inhibitors and ARBs'</a>.)</p><p class="headingAnchor" id="H4"><span class="h4">Race</span><span class="headingEndMark"> — </span>Although Black patients have a lesser antihypertensive response than White patients to RAS inhibitors [<a href="#rid11">11</a>], the bulk of evidence supports similar cardiovascular protection in patients with HF [<a href="#rid11">11</a>]. As a result, it is generally recommended that Black patients be treated the same as White patients.</p><p class="headingAnchor" id="H5"><span class="h4">Dosing</span><span class="headingEndMark"> — </span>Dosing and titration of RAS inhibitors in patients with HFrEF is presented elsewhere in detail. (See  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Dosing'</a>.)</p><p>Nonsteroidal antiinflammatory drugs (NSAIDs) can reduce the hemodynamic improvement associated with RAS inhibitors in advanced HF and should therefore be avoided. The vasoconstriction induced by angiotensin II in HF is partially ameliorated by the release of vasodilator prostaglandins; blocking this response with NSAIDs may minimize the degree to which the vascular resistance falls after the administration of an RAS inhibitor. Alternate analgesics should be considered whenever possible; if NSAIDs must be used, the dose and duration of therapy should be minimized [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects", section on 'NSAIDs and heart failure'</a>.)</p><p class="headingAnchor" id="H2614166155"><span class="h4">Combination angiotensin receptor-neprilysin inhibitors</span><span class="headingEndMark"> — </span>In patients who have symptomatic HF and reduced ejection fraction, drugs that combine an ARB with a neprilysin inhibitor are generally preferred in place of an ACE inhibitor or ARB. The use of these drugs is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'General cautions'</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Beta blockers</span><span class="headingEndMark"> — </span>Certain beta blockers, including <a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">carvedilol</a>, <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> succinate, and <a class="drug drug_general" data-topicid="9158" href="/d/drug information/9158.html" rel="external">bisoprolol</a>, have been shown to improve overall and event-free survival in patients with mild to advanced HF (<a class="graphic graphic_figure graphicRef75356" href="/d/graphic/75356.html" rel="external">figure 3</a>). The improvement in survival appears to be additive to that induced by ACE inhibitors. Beta-blocker therapy should be considered, independent of hypertension, in patients with New York Heart Association (NYHA) class II, III, or IV HF who have been stabilized on an ACE inhibitor and diuretics. Carvedilol may be particularly useful for blood pressure lowering in patients with HF. (See  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a>.)</p><p>Beta blockers can also provide anginal relief in patients with ischemic heart disease and provide rate control in patients with atrial fibrillation. (See  <a class="medical medical_review" href="/d/html/1466.html" rel="external">"Beta blockers in the management of chronic coronary syndrome"</a> and  <a class="medical medical_review" href="/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a>.)</p><p class="headingAnchor" id="H8"><span class="h4">Dosing</span><span class="headingEndMark"> — </span>Beta blockers in patients with systolic HF are usually begun with very low doses; these issues are discussed in detail elsewhere [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a>.)</p><p class="headingAnchor" id="H2901165622"><span class="h3">Mineralocorticoid receptor antagonists</span><span class="headingEndMark"> — </span>In addition to fluid removal with loop diuretics, mineralocorticoid receptor antagonists (<a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> [25 mg] or <a class="drug drug_general" data-topicid="8789" href="/d/drug information/8789.html" rel="external">eplerenone</a> at a dose of 50 mg/day) have been shown to improve survival in patients with advanced HF (<a class="graphic graphic_figure graphicRef76232" href="/d/graphic/76232.html" rel="external">figure 4</a>) [<a href="#rid14">14</a>] or in patients with a recent myocardial infarction and left ventricular dysfunction [<a href="#rid15">15</a>]. There is evidence for at least two mechanisms of benefit: an elevation in the serum potassium concentration, and prevention of the toxic effect of hyperaldosteronism on the heart. These issues are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Diuretics</span><span class="headingEndMark"> — </span>Diuretic therapy for signs of fluid overload (pulmonary and/or peripheral edema) is usually initiated with a loop diuretic (eg, <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a>). The fall in intracardiac filling pressure that results from diuretic-induced fluid removal may lower blood pressure, particularly when the renin-angiotensin system is inhibited. In hypervolemic individuals, cardiac output is usually not affected, although excessive diuresis may reduce cardiac output. (See  <a class="medical medical_review" href="/d/html/3512.html" rel="external">"Use of diuretics in patients with heart failure"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Other antihypertensive drugs</span></p><p class="headingAnchor" id="H3948566578"><span class="h3">Hydralazine/nitrates</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a> and <a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">isosorbide dinitrate</a> may be beneficial in patients with HF who were already being treated with standard therapies [<a href="#rid16">16</a>]. However, it requires multiple daily doses and may produce more side effects than an ACE inhibitor.</p><p class="headingAnchor" id="H740841786"><span class="h3">Calcium channel blockers</span><span class="headingEndMark"> — </span>Studies show a deleterious decrease in cardiac function of many calcium channel blockers in patients with HF. <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">Amlodipine</a> and <a class="drug drug_general" data-topicid="8438" href="/d/drug information/8438.html" rel="external">felodipine</a>, however, do not decrease cardiac function or increase mortality [<a href="#rid17">17,18</a>]. Thus, while there is no direct role for these drugs in the management of HF, amlodipine and felodipine appear to be safe and well tolerated and can be used for the treatment of coexisting hypertension. (See  <a class="medical medical_review" href="/d/html/3455.html" rel="external">"Calcium channel blockers in heart failure with reduced ejection fraction"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">TREATMENT OF HYPERTENSION IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)</span><span class="headingEndMark"> — </span>The optimal therapy of hypertension in patients with HFpEF (ie, diastolic dysfunction) is uncertain. Therapy in such patients, which usually consists of diuretics and, if tolerated, mineralocorticoid receptor antagonists [<a href="#rid19">19</a>], is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Pharmacotherapy'</a>.)</p><p>Diuretics and venodilators (such as nitrates) must be used cautiously because patients with a small, stiff left ventricular chamber are particularly susceptible to excessive preload reduction, which can lead to underfilling of the left ventricle, a fall in cardiac output, and hypotension [<a href="#rid20">20</a>]. However, they are often needed for symptomatic relief of dyspnea that is secondary to fluid overload.</p><p>Goal blood pressure in patients with HFpEF is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with heart failure'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Regression of left ventricular hypertrophy (LVH)</span><span class="headingEndMark"> — </span>LVH is frequently present in patients with diastolic dysfunction. Regression of LVH is an important therapeutic goal since diastolic function may be improved [<a href="#rid21">21</a>]. A meta-analysis published in 2003 evaluated the relative efficacy of different antihypertensive drugs for their ability to reverse LVH in patients with hypertension [<a href="#rid22">22</a>]. Eighty trials that included 146 and 17 active treatment and placebo arms, respectively, were evaluated. After statistical adjustments for length of therapy and degree of blood pressure lowering, the relative reductions in left ventricular mass index were (<a class="graphic graphic_figure graphicRef82558" href="/d/graphic/82558.html" rel="external">figure 5</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>ARBs – 13 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium channel blockers – 11 percent</p><p class="bulletIndent1"><span class="glyph">●</span>ACE inhibitors – 10 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Diuretics – 8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Beta blockers – 6 percent</p><p></p><p>The clinical significance of these differences is unknown because the effect of LVH regression on long-term clinical outcomes is not clear.</p><p class="headingAnchor" id="H3402462403"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension is the most prevalent modifiable risk factor for the development of heart failure (HF), both because hypertension increases cardiac work, which leads to the development of left ventricular hypertrophy (LVH), and because hypertension is a risk factor for the development of coronary heart disease. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of hypertension in patients with HF must take into account the type of HF that is present: systolic dysfunction, in which impaired cardiac contractility is the primary abnormality; or diastolic dysfunction, in which there is a limitation to diastolic filling and therefore in forward output due to increased ventricular stiffness. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, patients with hypertension and HF with reduced ejection fraction (HFrEF) should be treated, if possible, with a renin angiotensin system (RAS) inhibitor (ie, an angiotensin receptor-neprilysin inhibitor, angiotensin converting enzyme [ACE] inhibitor, or an angiotensin receptor blocker [ARB]), a beta blocker, and a mineralocorticoid receptor antagonist. In addition to the mortality benefit associated with this regimen in patients with HFrEF, many patients will experience improvement in their ejection fraction. (See <a class="local">'Renin-angiotensin antagonists'</a> above and <a class="local">'Beta blockers'</a> above and <a class="local">'Mineralocorticoid receptor antagonists'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diuretics are used to treat symptomatic hypervolemia (pulmonary and/or peripheral edema) or to further reduce blood pressure, if needed, in hypervolemic patients. (See <a class="local">'Diuretics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal therapy of hypertension in patients with HF and preserved ejection fraction (ie, diastolic dysfunction) is uncertain; most antihypertensive agents can reduce left ventricular mass. (See <a class="local">'Treatment of hypertension in patients with heart failure with preserved ejection fraction (HFpEF)'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dunlay SM, Weston SA, Jacobsen SJ, Roger VL. Risk factors for heart failure: a population-based case-control study. Am J Med 2009; 122:1023.</a></li><li><a class="nounderline abstract_t">Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417.</a></li><li><a class="nounderline abstract_t">Piller LB, Baraniuk S, Simpson LM, et al. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation 2011; 124:1811.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43:1439.</a></li><li><a class="nounderline abstract_t">Mant J, Al-Mohammad A, Swain S, et al. Management of chronic heart failure in adults: synopsis of the National Institute For Health and clinical excellence guideline. Ann Intern Med 2011; 155:252.</a></li><li><a class="nounderline abstract_t">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:1269.</a></li><li><a class="nounderline abstract_t">SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293.</a></li><li><a class="nounderline abstract_t">SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685.</a></li><li><a class="nounderline abstract_t">Packer M, Lee WH, Medina N, et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106:346.</a></li><li><a class="nounderline abstract_t">Sakata Y, Shiba N, Takahashi J, et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J 2015; 36:915.</a></li><li><a class="nounderline abstract_t">Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529.</a></li><li><a class="nounderline abstract_t">Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20:1549.</a></li><li><a class="nounderline abstract_t">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:1810.</a></li><li><a class="nounderline abstract_t">Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.</a></li><li><a class="nounderline abstract_t">Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.</a></li><li><a class="nounderline abstract_t">Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049.</a></li><li><a class="nounderline abstract_t">Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335:1107.</a></li><li><a class="nounderline abstract_t">Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96:856.</a></li><li><a class="nounderline abstract_t">Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370:1383.</a></li><li><a class="nounderline abstract_t">Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012; 59:442.</a></li><li><a class="nounderline abstract_t">Wachtell K, Bella JN, Rokkedal J, et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002; 105:1071.</a></li><li><a class="nounderline abstract_t">Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41.</a></li></ol></div><div id="topicVersionRevision">Topic 3838 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19854330" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Risk factors for heart failure: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052124" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21969009" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15093881" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844551" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of chronic heart failure in adults: synopsis of the National Institute For Health and clinical excellence guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133354" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2057034" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1463530" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3028221" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25637937" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742294" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1452929" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23741057" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10471456" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668699" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15533851" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8813041" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264493" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24716680" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Spironolactone for heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22281246" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11877357" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867233" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
